EM2008E "Treatment of Advanced Hepatocellular Carcinoma: Updates and Unmet Needs" (IM GR-082120)

To review HCC biology, genetics, surveillance, diagnosis, and systemic therapy. This lecture will focus on updates in HCC systemic therapy and provide an overview of immunotherapy resistance mechanisms.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify the three main categories of treatment for HCC based on stage: early, intermediate, and advanced.
  • Understand that the standard of care for advance HCC is changing rapidly, but that Atezolizumab + bevacizumab, and not sorafenib, is the new standard of care for appropriate patients.
  • Understand that immunotherapy resistance is divided into primary and acquired, tumor intrinsic and extrinsic mechanisms.
  • Understand that tumor mutational burden is one of many critical intrinsic factors that regulates treatment sensitivity.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: Hao Zhu, M.D.Hao Zhu, M.D.
Associate Professor
Children’s Research Institute & Department of Internal Medicine
Division of Hematology & Oncology

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome